Predicting factors of interstitial lung disease in dermatomyositis and polymyositis

Acta Dermato-Venereologica

Volumn 87, Issue 1, 2007, Pages 33-38

  Chen, Yi Ju ^a,b   Wu, Chun Ying ^a,c   Shen, Jui Lung ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dermatomyositis; Interstitial lung disease; Lactate dehydrogenase level; Polymyositis; Predicting factor

Indexed keywords

ANTIBODY; JO1 ANTIBODY; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; COUGHING; DERMATOMYOSITIS; DISEASE PREDISPOSITION; DYSPNEA; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; ONSET AGE; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; DERMATOMYOSITIS; FEMALE; HUMANS; LACTATE DEHYDROGENASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846881372     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0177     Document Type: Article

References (26)

1. Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 1982; 6: 253-259.
2. Miller FW. Polymyositis and dermatomyositis. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine, 22nd edition. Philadelphia: Saunders, 2004: p. 1680-1684.
3. Marie I, Harton PY, Hachulla E, Wallaert B, Michon-Pasturel, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998; 25: 1336-1343.
4. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tomling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297-301.
5. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-622.
6. Lakhanpal S, Lei JT, Conn DL, Martin WJ II. Pulmonary disease in polymyositis/dermatomyositis: a clinicopathologic analysis of 65 autopsy cases. Ann Rheum Dis 1987; 46: 23-29.
7. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18: 29-37.
8. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miwamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987; 14: 102-107.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-347, 403-407.
10. Ansell BM. Juvenile dermatomyositis. Rheum Dis Clin North Am 1991; 17: 931-941.
11. Fathi M, Lundberg E. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17: 701-706.
12. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993; 270: 1846-1849.
13. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. Anew approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-374.
14. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respiratory 2006; 11: 164-168.
15. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158: 1680-1684.
16. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. RadioGraphics 2002; 22: S151-S165.
17. Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32: 58-64.
18. Chen Y, Wu C, Shen J. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144: 825-831.
19. Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL Jr. Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis. Cutis 1998; 61: 190-194.
20. Benbassat J, Gefel D, Larholt K. Prognostic factors in polymyositis/dermatomyositis. Arthritis Rheum 1985; 28: 249-255.
21. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263-274.
22. Callen JP. Collagen vascular disease. J Am Acad Dermatol 2004; 51: 427-439.
23. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Rheumatol 2000; 12: 492-497.
24. Callen JP. Dermatomyositis. Lancet 2000; 355: 53-57.
25. Briemberg HR, Amato AA. Dermatomyositis and polymyositis. Curr Treat Opt Neurol 2003; 5: 349-356.
26. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38: 383-392.